Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy

Transplantation

Volumn 69, Issue 9, 2000, Pages 1849-1855

  Serón, Daniel ^a   Moreso, Francesc ^a   Ramón, Josep M ^a   Hueso, Miquel ^a   Condom, Enric ^a   Fulladosa, Xavier ^a   Bover, Jordi ^a   Gil Vernet, Salvador ^a   Castelao, Alberto M ^a   Alsina, Jeroni ^a   Grinyó, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; VASCULAR DISEASE;

EID: 0034657849     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005150-00019     Document Type: Article

References (34)

1. Dunn J, Golden D, Van Buren CT, Lewis RM, Lawen J, Kahan B. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990; 49: 349.
2. O'Neill BJ, Pflugfelder PW, Singh NR, Menkis AH, McKenzie FN, Kostuk WJ. Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantation. Am J Cardiol 1989; 63: 1221.
3. Paul LC, Häyry P, Foegh M, et al. Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: Proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc 1993; 25: 2020.
4. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827.
5. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
6. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
7. Azuma H, Nadeau KC, Ishibashi M, Tilney NL. Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor. Transplantation 1995; 60: 1577.
8. Räisänen-Sokolowski A, Vuoristo P, Myllärniemi M, Yilmaz S, Kallio E, Häyry P. Mycophenolate mofetil inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transplant Immunol 1995; 3: 342.
9. Hunsicker LG, Bennet LE. Design of trials of methods to reduce late renal allograft loss: the price of success. Kidney Int 1995; 48 (suppl 52): 120.
10. Kasiske BL, Massy ZA, Guijarro C, Ma JZ. Chronic renal allograft rejection and clinical trial design. Kidney Int 1995; 48 (suppl 52): 116.
11. Tullius SG, Hanckock WH, Heemann U, Azuma H, Tilney NL. Reversibility of chronic renal allograft rejection. Transplantation 1994; 58: 93.
12. Isoniemi HM, Krogerus L, Von Willebrand E, Taskinen E, Ahonen J, Häyry P. Histopathological findings in well functioning long term renal allografts. Kidney Int 1992; 41: 155.
13. Dimény E, Wahlberg J, Larsson E, Fellström B. Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? Clin Transplant 1995; 9: 79.
14. Serón D, Moreso F, Bover J, et al. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997; 51: 310.
15. Nickerson P, Jeffry J, Cough J, et al. Identification of clinical and histological risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9: 482.
16. Nicholson ML, McCulloch TA, Harper SJ, et al. Early measurement of interstitial fibrosis predicts long-term renal function and graft survival in renal transplantation. Br J Surg 1996; 83: 1082.
17. Mosteller RD. Simplified calculation of body surface area [Letter]. N Engl J Med 1987; 317: 1098.
18. Griñó JM, Alsina J, Sabater R, et al. Antilymphoblast globulin, cyclosporine and steroids in cadaveric renal transplantation. Transplantation 1990; 49: 1114.
19. Griñó JM, Castelao AM, Serón D, et al. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized trial. Am J Kidney Dis 1992; 20: 603.
20. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
21. Moreso F, Serón D, Morales JM, et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 1998; 12: 198.
22. Grinyó JM, Gil-Vernet S, Serón D, et al. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft. Nephrol Dial Transplant 1998; 13: 2601.
23. Hourmant M, Bedrosian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 1996; 62: 1565.
24. Cox DR. Regression models and life-tables (with discussion). J R Stats Soc B 1972; 34: 187.
25. Armitage P. Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1971: 184.
26. Tuzcu EM, De Franco AC, Goormastic M, et al. Dichotomous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. J Am Cardiol 1996; 27: 839.
27. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
28. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med 1993; 328: 164.
29. Burke BA, Chavers BM, Gillingham KJ, et al. Chronic renal allograft rejection in the first 6 months posttransplant. Transplantation 1995; 60: 1413.
30. Wang H, Solez K, Kjellstrand CM, Cockfield SM. The importance of donor vascular pathology in determining renal allograft outcome [Abstract]. J Am Soc Nephrol 1998; 9: 702A.
31. Legendre C, Thervet E, Skhiri H, et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 1506.
32. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518.
33. Isoniemi HM, Taskinen E, Häyry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994; 58: 1195.
34. Dimény E, Tufveson G, Lithell H, Larsson E, Siegbahn A, Fellström B. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993; 23: 572.